ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM)
Sylvia C. Kurz(Center for Neuro-Oncology), David Zagzag(NYU Langone Health), Lakshmi Nayak(Dana-Farber Cancer Institute), Tsivia Hochman(NYU Langone Health), John G. Golfinos(NYU Langone Health), Lori Magnelli(Ono Pharmaceutical (United States)), Isabel Arrillaga‐Romany(Harvard University), Eudocia Q. Lee(Brigham and Women's Hospital), Malcolm Delara(NYU Langone Health), Fraustina Hsu(NYU Langone Health), Erik P. Sulman(NYU Langone Health), Timothy F. Cloughesy(University of California, Los Angeles), Matija Snuderl, Joshua S. Silverman(NYU Langone Health), Jennie Taylor(University of California, San Francisco), Tooba Imtiaz(NYU Langone Health), Judith D. Goldberg(New York University), Amie Patel(NYU Langone Health)
Cited by 3
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k